# Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

> **NCT04829019** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 88 (estimated)

## Conditions studied

- Neurocognitive

## Interventions

- **RADIATION:** Osimertinib and whole-brain irradiation
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04829019
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-07
- **Primary completion:** 2024-04-01
- **Final completion:** 2025-10-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829019, "Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04829019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*